with a safety profile consistent with Bexsero and Menveo. GSK’s chief scientific officer, Tony Wood, said that the results show the vaccine protects against “the broadest panel of circulating ...

Penmenvy combines the antigenic components of two existing meningococcal vaccines from GSK: Bexsero and Menveo. GSK shares were down 1.0% to 1,421.00 pence early Monday in London.

Who Are the Major Players in the Menveo Market? Leading the Menveo market is GlaxoSmithKline (GSK) Plc, a key player driving innovation in vaccine development. Market leaders continually invest in ...